Reezo

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Reezo

Property Description
Active ingredient Piperacillin, Tazobactam Sodium Salt
Form Sterile Powder for Solution for Injection
Pharmacological class beta-lactam/beta-lactamase Inhibitor Combination
Common use Management of severe bacterial infections
Origin Synthetic, Fixed-Dose Combination Product

Reezo is the trade name for a combination antibacterial drug containing the two active ingredients, Piperacillin and Tazobactam Sodium Salt. It is classified within the pharmacological group known as a Penicillin-class Antibacterial and beta-lactamase Inhibitor combination. This specific pairing is clinically recognized for its reliable efficacy against a broad range of clinically relevant pathogens.

This medicinal entity is a synthetic, fixed-dose product designed for systemic use in hospital settings. The combination is globally utilized, with established brands like Zosyn and Tazocin using the same formulation, distinguishing it as a standard of care for severe nosocomial (hospital-acquired) infections.

Composition and Physical Form

The two principal components are Piperacillin Sodium Salt, which acts as the main anti-infective agent, and Tazobactam Sodium Salt, which serves to protect the anti-infective component. Reezo is provided as a sterile powder for solution for injection—a physical form that must be mixed with a compatible liquid before administration. The preparation is designed for the parenteral route of administration, delivered intravenously, which is essential when treating conditions that require immediate, high-level antibiotic concentration.

General Purpose and Benefit of this Combination

The general purpose of Reezo is to provide potent, broad-spectrum bactericidal activity for the management of serious or complex bacterial infections. A typical neutral use scenario involves treating a critically ill patient with a severe systemic infection where the causative organism is suspected of producing resistance enzymes. The key benefit of this dual-agent approach is that it overcomes one of the most common forms of bacterial defense: the production of beta-lactamase enzymes. By neutralizing these enzymes, Tazobactam preserves Piperacillin’s power to destroy the bacterial cell wall, ensuring the treatment's potency against difficult-to-treat organisms.

Regulatory References

  1. Piperacillin and Tazobactam Injection - DailyMed (NIH)

What side effects are possible with Reezo?

Possible Side Effects and Safety Information

The safety profile for Reezo (Piperacillin/Tazobactam) is officially documented by regulatory authorities, classifying potential adverse reactions by frequency and physiological system. Reactions are categorized into tiers such as Most Common (or Very Common/Common), Uncommon, and Rare.

Most frequently reported adverse reactions include diarrhea, nausea, vomiting, constipation, headache, insomnia, fever (pyrexia), and rash. These are generally classified under Gastrointestinal Disorders and Nervous System Disorders. Effects documented under the Blood and Lymphatic System include thrombocytopenia, leukopenia, and anemia.

Serious Adverse Reactions and Safety Constraints

Official labeling highlights severe adverse reactions requiring close attention. These include potentially fatal severe hypersensitivity reactions (anaphylaxis) and life-threatening Severe Cutaneous Adverse Reactions (SCARs) such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). Serious effects affecting organ systems include Acute Kidney Injury (AKI) and Convulsions (seizures), which are documented risks, especially at high doses.

Safety constraints noted in regulatory documents include a strict contraindication for individuals with a history of allergy to any penicillin or other beta-lactam antibiotic. Furthermore, official safety notes indicate that co-administration with vancomycin may be associated with an increased incidence of AKI.

Population and Duration Patterns

The safety profile includes special considerations for patients with impaired renal function, who are noted to be at increased risk for neurological complications and bleeding manifestations. For extended or prolonged therapy, effects like leukopenia and neutropenia may occur, and symptoms of pseudomembranous colitis can manifest even after treatment has ended.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdosage of Reezo is officially documented in regulatory information as potentially leading to severe systemic effects. Given the composition of the drug, the primary clinical manifestations of overexposure include neurological complications such as convulsions (seizures) and neuromuscular excitability. Other documented manifestations may include nausea, vomiting, and diarrhea.

Severe Outcomes and Risk Factors

High doses are associated with severe outcomes, including acute kidney injury (AKI) and nephrotoxicity. Patients with impaired renal function are identified in official labeling as being at a significantly greater risk for developing these neurological and renal complications when receiving higher doses. Additionally, bleeding manifestations linked to abnormalities in coagulation are also noted.

Mandated Emergency Actions

If overdosage is suspected, regulatory guidance mandates that patients or caregivers seek immediate medical attention and contact a poison control center or emergency room at once. The antibiotic must be discontinued upon the onset of severe symptoms like seizures or progressive systemic reactions. Treatment is officially described as supportive and symptomatic. Haemodialysis is documented as a known interventional procedure that can effectively reduce excessive serum levels of both Piperacillin and Tazobactam.

Therapeutic Uses of Reezo

Reezo is a therapeutic option generally used for the management of serious bacterial infections, particularly when symptoms are driven by difficult-to-treat organisms. It is commonly used across conditions presenting with acute episodes, including severe hospital-acquired pneumonia, complicated intra-abdominal infections like peritonitis, skin and soft tissue infections, and the management of fever in immunocompromised patients (febrile neutropenia).

The therapeutic benefit is in providing broad support across critical clinical settings that involve acute or unstable symptom patterns, such as sepsis or where the infection is caused by drug-resistant bacteria. This approach is considered relevant when managing heightened systemic burden, and may assist with managing symptoms associated with resistant bacteria. This broad action assists with maintaining functional stability and supports patients during difficult episodes by easing distress. It is applied across domains where additional symptomatic support is needed for patients who are critically ill or part of a vulnerable group (e.g., pediatric patients aged two months and older).

Quick Fact: Support for Systemic Imbalance The medication is relevant for easing symptoms related to systemic imbalance and organ-specific functional stress, such as high fever and complications associated with deep infections.

Regulatory References

  1. NIH DailyMed Drug Information

Eligibility and Restrictions for Use

This section explains the official eligibility and non-eligibility rules for Reezo (Piperacillin/Tazobactam) as documented in government regulatory sources, such as the FDA and EMA.

Eligibility Summary

Classification Official Regulatory Status
Absolute Contraindication Patients with a history of severe hypersensitivity (e.g., anaphylaxis) to Piperacillin, Tazobactam, or any beta-lactam antibacterial (including penicillins and cephalosporins) must not use this medicine.
Age-Related Eligibility Approved for adults and pediatric patients 2 months of age and older. Use in children under 2 months of age is not established or not indicated in the official labeling.
Conditional Use Patients with renal impairment (kidney function below leq 40 mL/min) are eligible, but use is restricted and requires specific dosage adjustments as mandated by regulatory documents. Critically ill patients require mandatory monitoring of renal function.
Pregnancy/Lactation Use in pregnant women is permitted only if clearly indicated (when the benefit outweighs the unknown risk). Piperacillin is excreted in low levels in breast milk, and use during lactation is generally considered acceptable with monitoring.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Reezo, a combination product containing piperacillin and tazobactam, as detailed in government regulatory information.

Interactions Affecting Drug Exposure

Co-administration with certain medicines is documented to alter the body's handling of the active components or co-administered drugs. Probenecid inhibits the renal tubular secretion of both piperacillin and tazobactam, a transporter-mediated effect that leads to increased and prolonged plasma concentrations of both components. Similarly, Methotrexate clearance is reduced when co-administered with Reezo, resulting in elevated and sustained plasma levels of Methotrexate due to competition for renal elimination.

Pharmacodynamic and Systemic Effects

  • Anticoagulants: When Reezo is co-administered with anticoagulants, such as Warfarin, the official documentation requires frequent monitoring of coagulation parameters (e.g., PT/INR) due to a documented risk of abnormal coagulation tests.
  • Neuromuscular Blocking Agents: The co-administration of Reezo with agents like Vecuronium may prolong the effect of neuromuscular blockade.

Administration-Timing Interactions

Aminoglycosides (e.g., Tobramycin, Gentamicin) must be prepared and administered separately from Reezo due to a chemical incompatibility. Mixing these two classes of antibiotics in vitro can result in the inactivation of the aminoglycoside. This rule relates to physical compatibility, not a systemic interaction.

Population-Specific Interaction Notes

Co-administration with Vancomycin has been associated with an increased documented incidence of acute kidney injury (nephrotoxicity), particularly in critically ill patients. Furthermore, interactions involving renal clearance are generally considered to be potentially more significant in patients with underlying renal impairment, as drug elimination is already reduced.

Mechanism of Action

How Reezo Works

Targeting the Kv7 Potassium Channel System

Reezo acts as a Positive Allosteric Modulator (PAM) and activator of a specific family of voltage-gated potassium channels, known as Kv7 or KCNQ channels, primarily affecting the Kv7.2-7.5 subunits expressed on nerve cells. Its binding enhances the probability and function of these channels. This initial molecular interaction initiates a biochemical cascade that alters the electrical signal patterns within the central nervous system.

Modulating Neuronal Excitability via Hyperpolarization

By enhancing the function of the Kv7 channels, Reezo facilitates an increased outward flow of positively charged potassium ions ( K^+), a process called hyperpolarization. This physiological change stabilizes the nerve cell's resting membrane potential, reducing its capacity to generate and sustain high-frequency action potentials. The resultant suppression of excessive electrical firing contributes to a measurable change in the overall activity patterns of targeted neural pathways.

Dosage and Administration Information

How to Use Reezo — Administration Guidelines

Reezo (Piperacillin and Tazobactam) is a combination anti-infective agent intended for use under specialized medical supervision. The medication is supplied as a Sterile Powder for Solution for Injection and is administered exclusively via Intravenous (IV) Infusion. This parenteral route requires the powder to be reconstituted and subsequently diluted with specific compatible fluids (e.g., 0.9% Sodium Chloride) before administration.


Administration Summary

Instruction Detail
Route of Administration Exclusively by Intravenous (IV) Infusion.
Dosing Schedule (Adults) Standard Dose: 3.375 g per dose, in a fixed 8:1 ratio. Maximum daily dose is up to 18.0 g of the combination.
Preparation Requirements Powder must be reconstituted and then diluted with specific compatible intravenous fluids prior to infusion.
Age-Group Administration Rules Renal Impairment: Mandatory dose or frequency reduction is required based on creatinine clearance. Pediatric Patients (≥ 2 months): Dosing is calculated using a weight-based regimen.
Special Procedural Conditions The solution must be administered via IV infusion over a period of 30 minutes. The total course typically lasts 7 to 10 days.

Connection to the Overall Use Protocol

The official instructions establish Reezo as a parenteral treatment that requires specialized preparation, including reconstitution and dilution, before its 30-minute IV infusion. The use is structured by fixed-interval dosing (e.g., every six or eight hours) over a finite course of days, with a mandatory protocol for dose adjustment in patients with impaired renal function. This ensures the drug is delivered according to the standard in a supervised clinical environment.

Recent Clinical Evidence

Recent Clinical Evidence

Clinical research has explored the effects of Reezo (a sodium-glucose cotransporter 2 or SGLT2 inhibitor) in adults with Type 2 Diabetes Mellitus (T2DM). The primary purpose of these studies is to evaluate the change in blood sugar control and to explore the long-term impact on overall health markers.


Glycemic Control and A1C

Multiple large-scale, controlled studies have evaluated the change in average A1C levels (a measure of blood sugar control over time). These trials reported a change in A1C, which was evaluated over treatment periods often extending beyond 12 weeks. The research included comparative studies of the medication against other anti-diabetic treatments. Observations regarding body weight and blood pressure were also recorded during some trials, as these are important health markers for individuals with T2DM.


Cardiovascular and Renal Markers

Cardiovascular Outcome Trials (CVOTs) have explored the relationship between Reezo and long-term clinical markers, particularly in individuals with T2DM who have existing cardiovascular disease or high risk factors. Key studies evaluated whether changes in blood sugar were related to changes in markers linked to major cardiovascular events, such as non-fatal heart attack or stroke, and hospitalization for heart failure. The research also focused on kidney health, exploring the medication’s association with markers of chronic kidney disease progression.


Combination Use

Research evaluated whether combining Reezo with other common T2DM medications, such as Metformin, was associated with greater changes in glycemic control compared to either medication used alone. The primary focus of the research was the management of T2DM. The evidence remains focused on the use of Reezo as part of a comprehensive T2DM treatment plan.

Key Studies & References NICE Guideline: Type 2 diabetes in adults: management (NG28)

Frequently Asked Questions (FAQ)

Common questions about Reezo (FAQ)


Q: How is Reezo different from other similar treatments I've heard about?

Official information describes Reezo as a combination medicine containing two active components: the antibiotic Piperacillin and the beta-lactamase inhibitor Tazobactam. The Tazobactam component is described in official documents as protecting the Piperacillin component from degradation by certain bacterial defense enzymes.


Q: Does Reezo affect blood pressure?

Regulatory documents indicate that Reezo can potentially cause an electrolyte imbalance known as hypokalemia (low potassium), which may affect cardiovascular parameters. Additionally, some less common side effects reported in official documents include changes to blood pressure, such as hypotension (low blood pressure).


Q: Is there any research on long-term use of Reezo?

Official documents note that some adverse reactions, such as a drop in white blood cell counts (leukopenia or neutropenia), have been associated with prolonged therapy. Official documents describe the total duration for the entire treatment course as typically 7 to 10 days.


Q: How quickly does Reezo start working?

Since Reezo is given as an intravenous (IV) infusion, the components reach the bloodstream quickly. This provides high concentrations of the active ingredients immediately. Official documents describe the total treatment course as typically 7 to 10 days.


Q: Is Reezo the same as [Name of common competitor]?

Reezo is the specific brand name for the formulation containing Piperacillin and Tazobactam Sodium Salt. While the same active ingredients may be found in other products, Reezo refers only to this particular medicine.


Q: Can Reezo be taken with common over-the-counter pain relievers?

Regulatory documents list interactions with specific prescription medicines but do not specifically name common over-the-counter pain relievers, such as ibuprofen or acetaminophen. Official guidance encourages informing a healthcare provider about all medicines being taken.


Q: Can elderly patients use Reezo?

Clinical studies have included elderly patients. Official guidance indicates that dosage adjustments for all adult patients, including the elderly, are primarily based on kidney function due to the way the drug is eliminated from the body.


Q: What does it mean if Reezo has a 'black box warning'?

Reezo does not carry a formal FDA Boxed Warning (which is often called a 'black box warning' by the public). However, the official label does contain serious warnings regarding life-threatening adverse events, such as severe allergic reactions and the risk of acute kidney injury.


Q: Does Reezo interact with caffeine or alcohol?

Official drug labeling does not list a specific interaction with caffeine. Regarding alcohol, official guidance encourages patients to discuss the consumption of alcohol with a healthcare professional during treatment.


Q: Can I take Reezo if I have a history of liver problems?

Official regulatory documents indicate that no specific dosage adjustment is typically required in patients with hepatic cirrhosis (liver disease). However, the rate at which the body eliminates the components of the drug may be slightly altered.


Q: Is Reezo a controlled substance?

No. Official government classifications indicate that Reezo (Piperacillin/Tazobactam) is a prescription antibiotic drug. It is not listed as a scheduled controlled substance by regulatory bodies.


Q: Are there any food restrictions while taking Reezo?

Since this medication is administered exclusively as an intravenous infusion in a supervised clinical setting, there are no specific food restrictions listed in the official labeling related to its administration.


Q: Are there any vitamins or supplements that interact with Reezo?

The official product information details interactions with other prescription medications but does not specifically name vitamins or supplements. Official guidance encourages informing the healthcare team about all supplements being taken.


Q: Can Reezo cause dry mouth?

Dry mouth is not listed among the most common adverse reactions in official safety documentation. However, it has been reported as a rare or unclassified side effect in some post-marketing surveillance reports.


Q: What is the difference between brand-name Reezo and its generic form?

Both the brand-name Reezo and the generic versions contain the exact same active ingredients: Piperacillin and Tazobactam. The generic form is required to meet the same quality, strength, and safety standards as the brand-name product.


Q: Does stopping Reezo suddenly cause any issues?

As an antibiotic, Reezo is generally intended to be used for the full course described by a healthcare provider. Official labeling notes that a severe type of diarrhea, known as pseudomembranous colitis, can potentially occur even after the full treatment has been completed.


Q: Is Reezo known to cause drowsiness?

Drowsiness is not listed as a common side effect in official reports. However, rare effects involving the Central Nervous System (CNS) have been reported, particularly in patients with kidney problems, which may include episodes of severe sleepiness.


Q: Does the package insert for Reezo include a list of all side effects?

Yes. According to regulatory standards, the official labeling or Prescribing Information is required to include a list of all documented adverse reactions. These reactions are typically classified by how often they occur and which body system they affect.


Q: What is the purpose of the 'Warnings and Precautions' section for Reezo?

This section in the official drug information is intended to alert healthcare professionals and patients to important safety risks and necessary monitoring. Examples include warnings about severe allergic reactions and the requirement for monitoring kidney function during therapy.


Q: Does Reezo affect fertility?

Official regulatory documents state that studies in animals did not show evidence of the drug causing negative effects on fertility. Comprehensive, controlled data regarding effects on human fertility are not currently available.


Q: Are there different strengths of Reezo available?

Yes. The sterile powder for injection is available in multiple vial sizes, which represent different strengths of the fixed combination of Piperacillin and Tazobactam. This allows healthcare providers to accommodate various prescribed dosing regimens.


Q: Are there official patient education materials for Reezo?

Yes. Authoritative sources like the National Institutes of Health (NIH) and government regulatory agencies provide official, public-facing information, patient guides, and drug facts sheets for this medication.


Q: Is Reezo generally considered safe for driving or operating machinery?

Official documentation does not specifically address driving safety. Side effects such as dizziness and other Central Nervous System effects have been reported, and these may affect the ability to safely operate machinery.

How should Reezo be stored and disposed of?

Storage and Disposal of Reezo (Piperacillin/Tazobactam) - Official Requirements

Storage Component Official Regulatory Requirement
Unopened Vial Temperature Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F), with permitted excursions up to 30 C.
Protection and Container Protect the vial from light by keeping it in the original outer carton; keep container tightly closed before use.
Prepared Solution Stability The prepared (reconstituted/diluted) solution is stable for up to 48 hours when stored in a refrigerator (2 C to 8 C) or 24 hours at room temperature.
Handling Prohibition The prepared solution must not be frozen and should not be stored above 30 C.
Disposal Any unused product and waste material must be disposed of in accordance with local requirements for pharmaceutical waste.
Child Safety The medicine must be kept out of the sight and reach of children.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Reezo found in:

A-Z Index: